Cancer Therapy

NIH grant to be used for dendritic cell-based cancer vaccines

Published in Biotech Business Week, October 25th, 2004

Aastrom Biosciences, Inc., (ASTM) announced that it has received a $109,586 phase I Small Business Innovation Research (SBIR) grant entitled Dendritic Cell Subset for Enhanced Cancer Vaccine (Grant Number: 1 R43 CA105686-01A1) from the U.S. National Institutes of Health (NIH) National Cancer Institute.

The 8-month study will determine the efficacy and ability of the company's proprietary AastromReplicell System to enhance the immunostimulatory potency of dendritic cell-based cancer vaccines through its patented Single-Pass Perfusion technology. The principal investigator in the study is Douglas M. Smith, PhD, Immunology Program leader at Aastrom.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2004-10-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry